Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the present study we investigated the regulation of tyrosine hydroxylase (TH) by angiotensin II (Ang II) in an attempt to provide cellular and molecular evidence that this hormone has increased neuromodulatory actions in the spontaneously hypertensive (SH) rat brain. Neuronal cells in primary culture from the hypothalamus-brain stem of both normotensive [Wistar-Kyoto (WKY)] and SH rats have been used. These cultures mimic in vivo situations. Ang II caused a time-dependent increase in TH activity in WKY rat brain neurons. A maximal increase of 2.5-fold was observed with 100 nM Ang II in an actinomycin- and cycloheximide-dependent process. In addition, Ang II caused a parallel increase in TH messenger RNA (mRNA) levels, with a maximal stimulation of 5-fold in 4 h by 100 nM Ang II in WKY rat brain neurons. The stimulation of TH mRNA was mediated by the
AT1
receptor subtype, resulted from an increase in its transcription, and involved activation of phospholipase C and
protein kinase C
. Antisense oligonucleotide for c-fos attenuated Ang II stimulation of TH mRNA in a time- and dose-dependent fashion, indicating an involvement of c-fos as a putative third messenger in Ang II stimulation of TH. Ang II also caused stimulation of TH activity and its mRNA levels in neuronal cultures of SH rat brain by a mechanism similar to that observed for neuronal cultures of WKY rat brain, involving
AT1
receptors,
protein kinase C
, and c-fos. However, the stimulation of TH activity and that of TH mRNA were approximately 30% and 80% higher, respectively, in the SH rat brain neurons than those in the WKY rat brain neurons. In vivo experiments have been carried out to validate the elevated response of TH gene expression to Ang II in SH rat brain neuronal cultures. Ang II stimulated both TH activity and TH mRNA levels in the hypothalami and brain stems of adult WKY and SH rats. The level of stimulation in the brain of the SH rat was significantly higher than that in the WKY rat. These observations are consistent with an increase in
AT1
, receptor gene expression and suggest that increased TH gene expression could be the cellular/molecular basis for the greater neuromodulatory action of Ang II in the SH rat brain.
...
PMID:Angiotensin II regulation of tyrosine hydroxylase gene expression in the neuronal cultures of normotensive and spontaneously hypertensive rats. 875 88
Treatment of rabbits with angiotensin-converting enzyme (ACE)-inhibiting drugs increases Na(+)-K+ pump current (Ip) of isolated cardiac myocytes when intracellular Na+ is at near-physiological levels. To examine if effects of ACE inhibitors are related to angiotensin metabolism, we measured Ip in myocytes isolated from rabbits treated with the
AT1
receptor antagonist losartan. Ip was increased to levels similar to those after treatment with ACE inhibitors. Exposure of myocytes from captopril-treated rabbits to 10 nM angiotensin II (ANG II) for 45 min in vitro reduced Ip to levels similar to those of myocytes from untreated control rabbits. This rapid response to ANG II suggests that treatment with captopril had induced a functional change in preexisting pump units rather than synthesis of a new population of pumps. Consistent with this, we could not detect a change in Na(+)-K+ pump subunit mRNAs during treatment with captopril. The decrease in Ip of myocytes from captopril-treated rabbits induced by ANG II in vitro was blocked by pertussis toxin, bisindolylmaleimide I, and staurosporine. Exposure of myocytes to phorbol 12-myristate 13-acetate induced a decrease in Ip similar to that induced by ANG II. Thus ACE inhibitors regulate the Na(+)-K+ pump in myocytes via an effect on angiotensin metabolism. The regulatory mechanism appears to include the
AT1
receptor, a G protein, and
protein kinase C
.
...
PMID:Angiotensin-converting enzyme inhibitors regulate the Na(+)-K+ pump via effects on angiotensin metabolism. 876 43
The renal vasculature of young spontaneously hypertensive rats (SHR) responds to angiotensin II (ANG II) with exaggerated vasoconstriction, due in part to defective buffering by the adenosine 3',5'-cyclic monophosphate (cAMP) pathway. In vitro studies suggest greater activation of phospholipase C and
protein kinase C
(
PKC
) in cultured mesangial cells and vascular smooth muscle cells. The present studies evaluated the role of
PKC
activation in renal vascular responses to ANG II receptor activation and the relative contributions in SHR vs. Wistar-Kyoto control rats (WKY). Renal blood flow was measured in 8-wk-old anesthetized SHR and WKY pretreated with indomethacin. ANG II (2 ng) injection into the renal artery produced a transient 45-50% maximum reduction of renal blood flow in both rat strains. Intrarenal infusion of either staurosporine or chelerythrine into the renal artery effectively attenuated the vasoconstriction elicited by ANG II in a dose-dependent manner, with maximum inhibition of 60-70%. The
PKC
inhibitory effects were significant and independent of strain. Coadministration of the
PKC
inhibitors produced maximal inhibition similar to that observed with one agent, suggesting action via a common pathway. In other studies, the linkage of the
PKC
pathway to the
AT1
receptor was evaluated using sub and maximal doses of losartan to antagonize 50-80% of ANG II-induced vasoconstriction. The same degree of inhibition was observed when a
PKC
inhibitor was coadministered with losartan. These findings support the views that the
PKC
system is a major intracellular signaling pathway coupled to the
AT1
receptor in renal resistance vessels and that
PKC
activation is involved to similar degrees in the renal vasoconstriction elicited by ANG II in young WKY and SHR. Exaggerated vascular reactivity to vasoconstrictor agents in genetically hypertensive animals is probably due to a defect in cAMP generation in the presence of a normally operating
PKC
pathway.
...
PMID:Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats. 876 13
The action of angiotensin II (ANG II) was studied in single myocytes from rat portal vein, in which the cytoplasmic Ca++ concentration was estimated by emission from fluorescent dyes and the Ca++ channel current was measured with the whole-cell mode of the patch-clamp technique. ANG II stimulated Ca++ channel current through L-type Ca++ channels and initiated a slow and small increase in the cytoplasmic Ca++ concentration in cells in which intracellular Ca++ stores had been depleted by pretreatment with ryanodine and caffeine. Both Ca++ channel current stimulation and Ca++ responses were selectively inhibited by losartan, indicating activation of angiotensin
AT1
receptors. Activation of Ca++ channels by ANG II was insensitive to treatment with pertussis toxin and cholera toxin. Intracellular applications of anti-G alpha q/alpha 11 and anti-phosphatidylinositol antibodies had no effect on the ANG II-induced stimulation of Ca++ channel current, indicating that phosphatidylinositol-specific phospholipase C was not involved in this signaling pathway. Down-regulation of
protein kinase C
and application of an inhibitor of
protein kinase C
blocked the ANG II-induced effects. Tricyclodecan-9-yl xanthogenate (an inhibitor of non-phosphatidylinositol-specific phospholipases C and phospholipases D) but not propranolol (an inhibitor of phospholipase D-derived diacylglycerol formation) suppressed the ANG II-induced effects. These data suggest that phosphatidylcholine-specific phospholipase C is involved in the ANG II signaling pathway leading to stimulation of L-type Ca++ channels by
protein kinase C
.
...
PMID:Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes. 876 93
The actions of angiotensin II in the cardiovascular system are transmitted by two known and possibly some unknown angiotensin receptor types.
AT1
and AT2 both correspond to G-protein-coupled receptors with seven hydrophobic transmembrane domains, several N-glycosylation sites and a potential G-protein binding site. Cloning of coding regions and promoter sequences contributed to the understanding of receptor protein function and regulation. Angiotensin receptors with atypical binding properties for the known
AT1
- and AT2-specific ligands are expressed on human cardiac fibroblasts and in the human ulcrus. In several animal models, receptors with high affinity for angiotensin (1-7) have been described.
AT1
stimulation is mediated by the generation of phospholipid-derived second messengers, activation of
protein kinase C
, the MAPkinase pathway and of immediate early genes. Recently, phosphorylation and dephosphorylation of tyrosine kinases have been associated with
AT1
- and AT2-mediated signal transduction. ATR are regulated by phosphorylation, internalization, modification of transcription rate and mRNA stability. Regulation is highly cell and organ specific and includes upregulation of ATR in some pathophysiological situations where the renin angiotensin system is activated. Whereas the function of
AT1
in the cardiovascular system is relatively well established, there is little information regarding the role of AT2. Recent hypotheses suggest an antagonism between
AT1
and AT2 at the signal transduction and the functional level. Transgenic animal models, particularly with targeted disruption of the
AT1
and AT2 genes, suggest the contribution of both genes to blood pressure regulation. Genetic polymorphisms have been described in the
AT1
and AT2 gene or neighbored regions and are used to analyze the association between gene defects and cardiovascular diseases.
AT1
antagonists are now being introduced into the treatment of hypertension and potentially heart failure, and more interesting pharmacological developments are expected from the ongoing basic studies.
...
PMID:Molecular biology of angiotensin receptors and their role in human cardiovascular disease. 877 61
To understand the molecular mechanism by which the angiotensin II (AII) type 1 receptor (
AT1
receptor) transduces its biological signal, we examined the role of various signaling molecules involved in
AT1
receptor signaling in Chinese hamster ovary cells stably transfected with the
AT1
receptor.
AT1
receptor-transfected cells responded to AII treatment by inhibiting adenylyl cyclase, increasing the intracellular Ca2+ concentration, and activating
protein kinase C
(
PKC
) alpha and
PKC
epsilon. AII also activated the c-fos gene and mitogen-activated protein (MAP) kinases. The activation of
PKC
, the c-fos gene, and MAP kinases was blocked by inhibition of
PKC
induced by pretreatment with 12-O-tetradecanoylphorbol-13-acetate but not by pretreatment with pertussis toxin, suggesting that
PKC
couples to the activation of the the c-fos gene and MAP kinases. In addition, AII activated Raf-1 and MAP kinase kinase in a
PKC
-dependent manner. A dominant negative mutant of Ras had no effect on AII-induced MAP kinase or c-fos gene activation. Thus, the
AT1
receptor signals through Raf-1 and its downstream signaling molecules by a
PKC
-dependent mechanism that does not involve Ras activation.
...
PMID:Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism. 879 90
Mechanical stress plays a pivotal role in the development of cardiac hypertrophy during hemodynamic overload, and angiotensin (Ang) II secreted from stretched myocytes plays an important role in mechanical stretch-induced hypertrophy. In the present study, we examined stretch-induced expression of Ang II receptors in an in vitro stretch model using 1-day-old rat myocytes. Both Ang II type 1 receptor (AT1-R) and type 2 receptor (AT2-R) mRNA levels were upregulated by myocyte stretching with similar time courses: significant increases were evident 6 hours after stretching, maximal levels (2.8- and 3.3-fold, respectively) were observed at 12 hours, and these were sustained for up to 18 hours. Ang II receptor expression in fibroblast-rich cultures was not affected by stretching. Conditioned medium in which myocytes were stretched for 12 hours significantly downregulated
AT1
-R and AT2-R mRNA levels in recipient myocytes, and this effect was almost completely blocked by
AT1
-R antagonists but not AT2-R antagonists. Stretch-induced expression of
AT1
-R and AT2-R mRNAs was further increased by 27% and 31%, respectively, after pretreatment with
AT1
-R antagonists, suggesting that Ang II secreted from stretched myocytes downregulates both
AT1
-R and AT2-R. Western blot and binding assays showed that the number of
AT1
-Rs and AT2-Rs increased by 2.4- and 2.6-fold, respectively, without affecting receptor affinities. Inositol phosphate response to 0.5 mumol/L Ang II was enhanced 2.1-fold in stretched myocytes. Nuclear runoff assays and treatment with actinomycin D revealed that stretch-induced upregulation of
AT1
-R was mainly due to increased transcription, whereas that of AT2-R resulted from a stabilizing effect on AT2-R mRNA metabolism. Stretch-induced changes in levels of Ang II receptors were inhibited by genistein but not by H-7, staurosporin, and
protein kinase C
depletion or by BAPTA-AM. Exposure to cycloheximide did not affect stretch-induced changes. These findings indicate that nonsecretory pathways activated by myocyte stretching upregulate the expression of Ang II receptor subtypes transcriptionally and posttranscriptionally through mechanisms involving stretch-activated tyrosine kinases independently of de novo protein synthesis and that the
AT1
-R-mediated action of Ang II is functionally enhanced in stretched cardiac myocytes.
...
PMID:Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. 883 15
1. The effect of angiotension II (Ang) on delayed rectifier K+ current (IK(V)) was studied in isolated rabbit portal vein smooth muscle cells using standard whole-cell voltage clamp technique. The effect of 100 nM Ang on macroscopic, whole-cell IK(V) was assessed in myocytes dialysed with 10 mM BAPTA, 5 mM ATP and 1 mM GTP either at room temperature or at 30 degrees C. 2. Application of Ang caused a decline in IK(V) which was reversed upon washout of the drug. Tail current recorded after 250 ms pulses to +30 mV and repolarization to -40 mV was reduced from 3.9 +/- 0.7 to 2.5 +/- 0.5 pA pF-1 at 20 degrees C (n = 6) and from 4.5 +/- 0.5 to 3.13 +/- 0.4 pA pF-1 at 30 degrees C(n = 17). 3. Ang had no effect on outward current in the presence of an
AT1
selective antagonist, losartan (1 microM), which alone had no direct effect on the amplitude of IK(V). Substitution of extracellular Ca2+ with Mg2+ in the presence of 10 microM intracellular BAPTA did not affect the suppression of IK(V) by Ang. 4. Ang induced a decrease in time constant for the rapid phase of inactivation of the macroscopic current (tau 1 reduced from 377 +/- 32 to 245 +/- 11 ms; tau 2 unchanged, n = 17). Neither the voltage dependence of activation nor inactivation were affected by Ang. 5. The inhibition of IK(V) by Ang was abolished by intracellular dialysis with the selective
PKC
inhibitors, calphostin C (1 microM) and chelerythrine (50 microM). These data provide strong evidence that the decline in IK(V) due to Ang treatment is due to
PKC
activation. 6. The pattern of expression of
PKC
isoforms was examined in rabbit portal vein using isoenzyme-specific antibodies: alpha, epsilon and zeta isoenzymes were detected, but beta, gamma, delta and eta isoenzymes were not. 7. The lack of requirement for Ca2+, as well as the sensitivity of the Ang response to chelerythrine, suggest the involvement of the Ca(2+)-independent
PKC
isoenzyme epsilon in the signal transduction pathway responsible for IK(V) inhibition by Ang.
...
PMID:Angiotensin II activation of protein kinase C decreases delayed rectifier K+ current in rabbit vascular myocytes. 888 76
The discovery of new pharmacologic and biochemical tools has prompted intensive research on the intracellular mechanisms conveying the physiologic message carried by angiotensin II (A II). Virtually all the cardiovascular effects of A II are activated by mobilization of the calcium messenger system through the
AT1
-receptor subtype. The AT2 subtype, which is highly expressed in fetal tissues, appears to be silent in adult tissues but may play a role in growth-related functions. Several functional domains that are involved in distinct processes have been identified in the
AT1
receptor. Through a GTP-binding protein (Gq), A II activates a phospholipase C, which generates inositol 1,4,5-trisphosphate (Ins[1,4,5]P3) and diacylglycerol. Ins(1,4,5)P3 releases calcium from intracellular stores, which is a signal for a "capacitative" calcium influx. The net result of the various processes of calcium trafficking is an initial transient peak of cytosolic calcium concentration ([Ca2+]c) followed by a sustained response. A II also induces a translocation of
protein kinase C
(
PKC
) from the cytosol to the cell membrane.
PKC
can either potentiate or counteract the responses elicited by the [Ca2+]c changes. A II also alters the activity of voltage-gated calcium channels and of the sodium-calcium exchanger. Finally, the activity of adenylyl cyclase can also be affected. By contrast, the signaling mechanisms linked to the AT2-receptor subtype are poorly understood. The integration of these multiple and variable signals, as well as the cell's enzymatic repertory, eventually determine the specific cellular response. The unraveling of these complex mechanisms opens new perspectives for the development of therapeutic tools that could interfere more specifically with the intracellular processes of A II and its effects on the cardiovascular system.
...
PMID:Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. 891 39
Many lines of evidence have suggested that angiotensin II (Ang II)plays an important role in cardiac hypertrophy. Ang II not only increases protein synthesis but also induces the reprogramming of gene expression in cultured cardiac myocytes. In the present study, to elucidate the mechanism by which Ang II regulates gene expression in cardiac myocytes, we examined whether Ang II activates c-Jun NH2-terminal kinase (JNK), which is a member of the mitogen-activated protein kinase family and activates the transcription factor, activator protein-1 (AP-1). The activity of JNK increased 5 minutes after the addition of Ang II, peaked at 20 minutes, and gradually decreased thereafter. Examination of the Ang II dose-response relation revealed detectable JNK activation at 10(-9) mol/L and maximal activation at 10(-6) mol/L. Ang II activated JNK through the
AT1
receptor, and the activation was attenuated by the downregulation of
protein kinase C
or the chelation of intracellular Ca2+. Although the addition of either Ca2+ ionophore or phorbol ester resulted in little or no activation of JNK, simultaneous addition of both Ca2+ ionophore and phorbol ester markedly activated JNK. Slight expressions of the c-jun gene were observed in unstimulated cardiac myocytes, and Ang II increased expressions of the c-jun gene as well as the c-fos gene. Ang II increased transcription of the endothelin-1 gene through the AP-1 binding site. In conclusion, Ang II may activate JNK in cultured cardiac myocytes through an increase in intracellular Ca2+ and activation of
protein kinase C
, and the activated JNK may regulate gene expression by activating AP-1 during Ang II-induced cardiac hypertrophy.
...
PMID:Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. 897 32
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>